Key points from article :
Trimtech Therapeutics, a UK-based biotech company, has secured $31 million in seed funding to advance its targeted protein degradation therapies for neurodegenerative and inflammatory diseases. The funding will support the development of Trimtech’s proprietary aggregate-selective degraders, which aim to clear harmful protein aggregates linked to conditions such as Alzheimer’s and Huntington’s while preserving healthy proteins.
The company’s approach is based on TRIM21, an E3 ubiquitin ligase that selectively marks disease-causing protein clusters for degradation without affecting their functional monomers. Trimtech has developed two degrader platforms: TRIMTACs, which directly recruit TRIM21 to target proteins, and TRIMGLUEs, which facilitate interactions between TRIM21 and disease-causing aggregates. These innovative therapies address a key limitation of existing targeted protein degradation technologies, which often struggle to distinguish between harmful and essential proteins.
The oversubscribed financing round was led by Cambridge Innovation Capital and SV Health Investors’ Dementia Discovery Fund, with additional backing from Pfizer Ventures, M Ventures, and Eli Lilly. Trimtech CEO Nicola Thompson called the investment a strong endorsement of the company’s scientific foundation and potential to transform neurodegenerative disease treatment. Experts believe Trimtech’s technology could fill a major gap in drug discovery by enabling the selective removal of toxic protein aggregates, offering new hope for millions affected by Alzheimer’s and related conditions.
